Gut microbiome predicts gastrointestinal toxicity outcomes from chemoradiation therapy in patients with head and neck squamous cell carcinomaOriginal paper
Karen Pendergrass is a microbiome researcher specializing in microbiome-targeted interventions (MBTIs). She systematically analyzes scientific literature to identify microbial patterns, develop hypotheses, and validate interventions. As the founder of the Microbiome Signatures Database, she bridges microbiome research with clinical practice. In 2012, based on her own investigative research, she became the first documented case of FMT for Celiac Disease, four years before the first published case study.
Read MoreWhat was studied?
Researchers examined whether baseline gut microbiome composition predicts gastrointestinal toxicity from chemoradiation (CRT) in patients with locally advanced head and neck squamous cell carcinoma (HNSCC), focusing on mucositis severity.
How was it studied?
In a prospective study of 52 HNSCC patients, stool samples were collected before CRT from 47 patients and analyzed by shotgun metagenomic sequencing. Mucositis grading, enteral feeding need, and survival were tracked over a median follow-up of 26.5 months.
What did they find?
All patients developed mucositis, with 42 percent reaching severe grade 3 or higher and 25 percent needing enteral feeding. Severe mucositis was associated with shorter overall survival (HR 3.3, p = 0.02) and gut enrichment in Mediterraneibacter (Ruminococcus gnavus) and Clostridiaceae members including Hungatella hathewayi. Grade 1 to 2 mucositis instead showed enrichment in Eubacterium rectale, Alistipes putredinis, and Ruminococcaceae members.
Why it matters
Baseline gut microbiome profiles may help identify HNSCC patients at risk for severe CRT toxicity and poorer survival before treatment begins. The bacteria enriched in severe mucositis have separately been linked to immune checkpoint inhibitor resistance.